本帖最后由 老马 于 2012-1-13 21:20 编辑 6 J& _: ? u: Q- V+ e* B+ g! ^9 G
2 _( w# f$ b, F- }' f4 }) L
爱必妥和阿瓦斯丁的比较7 |- t6 N# Q& }6 z
1 n& `+ b$ m$ ~
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
7 @7 a- p" z8 D. ~
" O1 i% v* u$ a
* F; O9 i5 N; A1 R
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
7 f4 J5 r2 E- R2 K7 |" ^5 i================================================== n$ E% X' ` F7 i! l! [% ~
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ o! g; n8 R& E; ^* ZPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.0 m S" z8 l0 R2 ?2 l
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.1 ?' u5 K0 \3 Y q
|